Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
CARLSBAD, Calif., March 23, 2017 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the Company plans to participate in the 16th Annual Needham & Company Healthcare Conference in New York, NY.
SeaSpine's management is scheduled to present on Tuesday, April 4, 2017 at 11:20 a.m. ET. Interested parties can access the live audio webcast on the Investors page of the company’s website at http://www.seaspine.com.
About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact Lynn Pieper Lewis (415) 937-5402 [email protected]
